Bis zu 90% sparen! Kostenloser Depotgebühren-Check
030-275 77 6400
DAX-0,71 % EUR/USD-0,06 % Gold+0,48 % Öl (Brent)-2,45 %

SpePharm AG Wins Case Against Eisai Inc. in United States District Court for District of Delaware

Nachrichtenagentur: news aktuell
09.09.2019, 11:10  |  113   |   |   
Amsterdam (ots/PRNewswire) - SpePharm AG, a subsidiary of Norgine
B.V., announced that the United States District Court for the
District of Delaware ruled on 4th September 2019 in favour of
SpePharm in its proceeding against Eisai Inc., upholding SpePharm's
licensed rights for SALAGEN® (pilocarpine hydrochloride) through
April 2026. Judge Richard Andrews upheld SpePharm's position, finding
that SpePharm properly exercised its option to extend its license
agreement in 49 countries.

Eisai Inc. purported to give notice of its intent to terminate
SpePharm AG's exclusive licensed rights for SALAGEN, a drug used to
treat dry mouth caused by radiation therapy for head and neck cancer
and to treat dry mouth and dry eyes in individuals with Sjögren's
syndrome, and had entered into an agreement to sell global rights to
SALAGEN to Advanz Pharma Corp. The Court's decision confirms that
SpePharm retains its rights in 49 countries in Europe and the
Commonwealth of Independent States through April 2026.

Speaking on behalf of SpePharm, Peter Stein (CEO of Norgine) said,
"We are gratified that the Court speedily agreed with SpePharm's
position and upheld SpePharm's rights to continue commercialising
SALAGEN for the benefit of patients. We are disappointed that we had
to resort to legal action against Eisai, however, SpePharm will
vigorously defend its rights through all appropriate means."

www.norgine.com

Follow us @norgine

Notes to editors:

About SpePharm

SpePharm AG is an independent unit within the Norgine group of
companies and is based in Werftestrasse in Lucerne.

Norgine is a leading European specialist pharmaceutical company
that has been bringing transformative medicines to patients for over
a century. Across the globe in 2018, Norgine is proud to have helped
23 million patients and generated EUR395 million in net product sales
to reinvest in medicines for the future, a growth of 15% over 2017.

We understand the complexities of the European healthcare systems
and have a direct presence in 14 European countries, as well as
Australia and New Zealand. We also have a strong global network of
partnerships in non-Norgine markets.

We are a flexible and fully integrated pharmaceutical business,
with manufacturing (Hengoed, Wales and Dreux, France), third party
supply networks and significant product development capabilities, in
addition to our sales and marketing infrastructure. This enables us
to acquire, develop and commercialise specialist and innovative
products that make a real difference to the lives of patients around
the world.

Logo - https://mma.prnewswire.com/media/597589/Norgine_Logo.jpg

ots Originaltext: Norgine
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Clara Bentham +44-(0)1895-826654 or +44-(0)7734-367883

contact@norgine.com
Diesen Artikel teilen
Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
EuroEURInternetFranc


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel
Aus der Community
LUS Wikifolio-Index BITCOIN performance Index Zertifikat Open-End (LASW)
Chart: arniarni
LUS Wikifolio-Index BITCOIN, ETHEREUM & GOLD Index Zertifikat Open-End (LASW)
Chart: arniarni
LUS Wikifolio-Index Sehr bekannte Kryptowaehrung Index Zertifikat Open-End (LASW)
Chart: arniarni